Nextleaf Solutions Reports Fiscal Q2 2026 Results
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) ("Nextleaf" or the "Company") a multi-patented Canadian cannabis processor, announced financial results for Q2 FY2026 (ended March 31, 2026), with gross revenue of $3,338,310 and gross profit of $914,536 (38% gross margin). The quarter reflects deliberate investment in commercial infrastructure, including a national sales agency, qualified export ready platform, and a second
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-06-01 9:30 AM EDT | Nextleaf Solutions Ltd.
Telescope Innovations Secures Third Self-Driving Lab Deployment with Major Global Pharmaceutical Company
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a leading developer of intelligent automation and advanced chemical manufacturing technologies, today announced that is has signed an agreement with a major global pharmaceutical company to deliver a Self-Driving Lab (SDL) platform at the company's European operations. The deployment, Telescope's third SDL pla
Technology, Chemical, Pharmaceuticals
2026-06-01 8:00 AM EDT | Telescope Innovations Corp.
CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation
Houston, Texas--(Newsfile Corp. - June 1, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company focused on cannabinoid biotechnology, applied research, and therapeutic innovation, today announced the completion of a patent-ready melanoma research program focused on cannabinoid science, oncology biology, aging-related cellular stress, and epigenetic regulation. The Company views this milestone as part of its broader strategy to build research-driven int
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-06-01 7:00 AM EDT | Cannabis Bioscience International Holdings
Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product
Northvale, New Jersey--(Newsfile Corp. - June 1, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for a generic drug product in the class of medications called anticoagulants. IQVIA reported branded product sa
Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-01 7:00 AM EDT | Elite Pharmaceuticals, Inc.
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - June 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Lambert to its Board of Directors, effective immediately. Dr. Lambert brings more than four decades of scientific leadership and pioneering expertise in the development of antibody-drug conjugates ("ADCs"), f
Biotechnology, Pharmaceuticals, Health
2026-06-01 3:15 AM EDT | Defence Therapeutics Inc.
Herbal Dispatch Reports First Quarter 2026 Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis e-commerce and distribution platform, today reported its financial results for the three months ended March 31, 2026 and provided an update on the Company's strategic initiatives and operational progress. Strategic Transition Underway During the first quarter of 2026, Herbal
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-06-01 3:00 AM EDT | Herbal Dispatch Inc.
Theralase(R) Releases Q1 2026 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's unaudited interim consolidated financial statements for the three-month period ended March
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-05-29 5:04 PM EDT | Theralase Technologies Inc.
Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian
Montreal, Quebec--(Newsfile Corp. - May 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, announces that Dr. Sarkis Meterissian resigned today from the Board of Directors of Defence to deepen engagement with the Company by joining the Scientific Advisory Board ("SAB"). Defence Therapeutics' current SAB is composed of Rob Leanna, PhD,
Biotechnology, Pharmaceuticals, Health
2026-05-29 4:30 PM EDT | Defence Therapeutics Inc.
NuGen Medical Devices Files Patent for Dual Spring Technology Enhancing Needle-Free Injection Performance
Toronto, Ontario--(Newsfile Corp. - May 28, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle free drug delivery, today announced the filing of a new patent application (Reference No. P105204NL) covering a new fluid injection technology designed to optimize pressure profiles in needle-free drug delivery systems. The new technology enables a controlled, multi-phase injection profile that delivers the high pressure needed for reli
Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-28 1:43 PM EDT | NuGen Medical Devices Inc.
PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines
Toronto, Ontario--(Newsfile Corp. - May 27, 2026) - PharmaTher Holdin
Biotechnology, Pharmaceuticals
2026-05-27 8:00 AM EDT | PharmaTher Holdings Ltd.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-26 7:00 AM EDT | Phio Pharmaceuticals Corp.
Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of a production run of naturally derived psilocybin extract measuring approximately 6% psilocybin content, representing the highest-purity botanical ps
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-26 7:00 AM EDT | Optimi Health Corp.
Herbal Dispatch Obtains Export Development Canada (EDC) Insurance to Support Accelerating International Growth
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis e-commerce and distribution platform, is pleased to announce that it has obtained export credit insurance coverage through Export Development Canada ("EDC") in support of its growing international cannabis export business. The EDC insurance coverage becomes active on June 1, 202
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-05-26 5:01 AM EDT | Herbal Dispatch Inc.
TempraMed Featured on Dr. Phil Show in National US Broadcast Highlighting the Risk of Temperature Exposure for Insulin and Other Medications
Vancouver, British Columbia--(Newsfile Corp. - May 22, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed a medical technology innovator transforming how temperature sensitive medications are stored and managed, is pleased to announce that TempraMed is featured on the Dr. Phil Show in a national broadcast episode focused o
Technology, Biotechnology, Pharmaceuticals, Health
2026-05-22 11:57 AM EDT | TempraMed Technologies Ltd.
Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today closed its previously announced underwritten public offering (the "Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company issued 2,400,000 common s
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-21 1:07 PM EDT | Optimi Health Corp.
Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU"
Reno, Nevada--(Newsfile Corp. - May 21, 2026) - Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, announced it has officially commenced trading on the Nasdaq today under the ticker symbol "CNXU." The Company currently has 25,269,996 shares on an issued and outstanding basis and 35,238,222 shares on a fully diluted basis.
Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-21 12:02 PM EDT | Conexeu Sciences Inc.
TMC Group Commissions New Capacity to Support Next-Generation Radiotheranostics
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - As demand for radiotheranostics continues to grow exponentially, TMC Group, a Canadian manufacturer of high-purity enriched stable isotopes, is commissioning new production lines this year. This will add 50 percent more capacity to help ensure reliable supply for radiopharmaceutical research, clinical development, and future commercialization. TMC Group will be exhibiting at the 2026 Society of Nuclear Medicine and Molecular
Technology, Biotechnology, Chemical, Pharmaceuticals
2026-05-21 10:00 AM EDT | TMC Group
Herbal Dispatch Completes Export of 261kg of Medical Cannabis to Europe
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis e-commerce and distribution platform, is pleased to announce the successful completion of a 261-kilogram international medical cannabis export shipment to Europe. The shipment represents another significant milestone in the continued expansion of Herbal Dispatch's international exp
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-05-21 5:01 AM EDT | Herbal Dispatch Inc.
Theralase(R) Closes C$4.8 Million Offering
Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has closed its previously announced brokered private placement offering ("Brokered Offering
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-05-20 11:06 AM EDT | Theralase Technologies Inc.
Sym Sciences Awarded $50,000 Grant to Advance IND-Ready Cannabinoid Research Platform
New York, New York--(Newsfile Corp. - May 20, 2026) - Sym Sciences announced today that it has been awarded a $50,000 grant from the to support the development of standardized, IND-ready cannabinoid materials for clinical research. The funding will enable Sym Sciences to expand its university research network and accelerate the preparation of regulatory-grade cannabinoid formulations designed for NIH-funded studies. The initiative is focused on streamlining the pathway from product deve
Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-20 8:25 AM EDT | Sym Sciences